The FDA has signaled that it will take a much more welcoming approach to the use of real-world data (RWD) and real-world evidence (RWE) in decision making regarding the approval of new drugs and biologics, with the release of a new framework for the regulatory use of such evidence.
Solutions
![right arrow](/Ontada/images/icons/white-down-arrow.png?v=u3hjhmpNIp8etEtmS7upEeqmDPfsRubUgmP7L488NAo)
Life Sciences
![right arrow](/Ontada/images/icons/blue-right-arrow.png?v=4KFZ6vCSu6sqTp58mSQjR0Tul-I-DKOrhnC2bAf3LXY)
News & Events
![right arrow](/Ontada/images/icons/blue-right-arrow.png?v=4KFZ6vCSu6sqTp58mSQjR0Tul-I-DKOrhnC2bAf3LXY)
More